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We studied five individuals from three Jewish Bukharian families affected by an apparently autosomal-recessive form of hereditary
spastic paraparesis accompanied by severe intellectual disability, fluctuating central hypoventilation, gastresophageal reflux disease,
wake apnea, areflexia, and unique dysmorphic features. Exome sequencing identified one homozygous variant shared among all affected
individuals and absent in controls: a 1 bp frameshift TECPR2 deletion leading to a premature stop codon and predicting significant
degradation of the protein. TECPR2 has been reported as a positive regulator of autophagy. We thus examined the autophagy-related
fate of two key autophagic proteins, SQSTM1 (p62) and MAP1LC3B (LC3), in skin fibroblasts of an affected individual, as compared
to a healthy control, and found that both protein levels were decreased and that there was a more pronounced decrease in the lipidated
form of LC3 (LC3II). siRNA knockdown of TECPR2 showed similar changes, consistent with aberrant autophagy. Our results are
strengthened by the fact that autophagy dysfunction has been implicated in a number of other neurodegenerative diseases. The discov-
ered TECPR2 mutation implicates autophagy, a central intracellular mechanism, in spastic paraparesis.Hereditary spastic paraparesis (HSP) is a diverse group of
neurodegenerative disorders estimated to affect 9.6 out
of 100,000 individuals. It is characterized by axonal degen-
eration of the corticospinal or pyramidal motor and
sensory tracts that control the lower extremities and results
in progressive spasticity and hyperreflexia of the lower
limbs.1–4 The disorder exhibits clinical variability with an
onset seen from early childhood through 70 years of age.
Pure HSP is characterized by progressive spasticity and
leg weakness and is often associated with autosomal-domi-
nant inheritance, whereas complicated HSP involves
lower-limb spasticity accompanied by other neurological
symptoms and tends to be autosomal recessive5 (also see
GeneReviews in Web Resources). Previously, 48 spastic-
paraplegia (SPG) loci for different HSP types (including
X-linked HSP) have been reported, and of these, 27 have
been associated with identified genes (Table S1, available
online).6 Because of the heterogeneity and the clinical
overlap in HSP, genetic diagnosis and testing have been
a daunting task.
We have encountered five individuals from three appar-
ently unrelated Jewish Bukharian families, which were
independently referred to the pediatric neurological clinic
at the Sheba Medical Center in Israel. Affected individuals
presented with what appeared to be autosomal-recessive
HSP of the complicated form. Four of the five individuals
were available for DNA-sequencing analysis (Figure 1A).
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members. All affected individuals were presented to the
clinic during the second year of life as a result of hypotonia
and developmental delay. They had short stature, mild
brachycephalic microcephaly, a round face, a low anterior
hairline, dental crowding, a short broad neck, and a chubby
appearance. The neurological phenotype included motor
and cognitive delay followed by moderate to severe intel-
lectual disability and hypotonia that, in four out of five
individuals who developed independent walking, evolved
until the end of the first decade of life into a spastic, rigid
ataxic gait. Speech, when present, was dysarthric, their
faces were hypomimic (although with a friendly disposi-
tion), and deep-tendon reflexes were absent. The more
cooperative individuals were dysmetric in a finger-to-
nose maneuver. All affected individuals had recurrent
pulmonary infections due to gastresophageal-reflux dis-
ease (MIM 109350). Ongoing severe central-apnea epi-
sodes were characteristic of all individuals initially during
sleep and evolved with age into the wake state. Four
of the individuals had recurrent episodes of decreased
alertness, aggravation of hypotonia, and inefficient respi-
ration requiring mechanical ventilation, and the younger
affected individuals experienced spontaneous remission
to the baseline. The oldest affected individual (II-2 in
family B), a 20-year-old female, did not recover from her
last episode and currently requires mechanical ventilation.
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Figure 1. Pedigrees and Neuroimaging
Phenotypes
(A) Pedigrees of the three Jewish Bukharian
families. Filled symbols represent affected
individuals, roman numerals indicate
generations, and numbers are serial within
the family. The slash represents the de-
ceased individual with DNA available
from a remaining muscle biopsy. TECPR2
genotype status for the c.3416delT variant
is indicated by DT/DT for a homozygous
mutation, DT/T for a heterozygous muta-
tion, and T/T for a wild-type form. Circles
indicate individuals who underwent
exome sequencing.
(B) A T1 sagittal MRI from individual II-1 in
family A shows a thin corpus callosum at
the age of 3 years.
(C) AT1 sagittalMRI from individual II-1 in
family A shows progressive cerebellar ver-
mian atrophy at the age of 10 years.
(D) A T2 axial MRI from individual II-2
in family C at the age of 7 years shows
enlarged lateral ventricles and deep sulci,
indicating cerebral atrophy.
(E) A T2 sagittal MRI from individual II-2
in family C at the age of 7 years shows
deep cerebral sulci (indicating cerebral
atrophy), a thin corpus callosum, and ver-
mian atrophy.metabolic decompensation. The two siblings from family
B (II-1 and II-2) had infrequent short generalized tonic-
clonic seizures. Individual II-1 from family A had recurrent
ankle pressure ulcers, and individual II-2 from family B had
transient severe encephalopathy with intermittent eleva-
tion of transaminases. Extensive metabolic testing was
normal for all. Individual II-1 from family B died at the
age of 5.5 years as a result of aspiration. MRI scans from
two individuals (II-1 in family A and II-2 in family C)
showed a thin corpus callosum, as well as cerebral and cere-
bellar atrophy (mainly vermian) (Figures 1B–1E). Muscle
biopsy from three individuals (II-1 and II-2 in family B
and II-2 in family C) showed normal histology, and respi-
ratory-chain studies revealed normal function. Polysom-
nograms showed very frequent central apneas (>90/hr)
accompanied by hypoxemia and poor response to oxygen1066 The American Journal of Human Genetics 91, 1065–1072, December 7, 2012enrichment. Electroencephalography
showed diffuse slowing with poor
background organization and no epi-
leptiform activity. Electromyography
(EMG) and nerve-conduction studies
were normal.
We performed exome sequencing
in the four available individuals. On
the basis of previous studies indi-
cating that Bukhara Jewish families
are distantly related7 and of the
inferred autosomal-recessive inheri-
tance in all three families, we ex-
pected a founder mutation and thusfocused on homozygous variants shared among all affected
individuals. Targeted exonic regions were captured by the
SureSelect Human All Exon kit (Agilent Technologies).
Samples were subsequently sequenced with a Genome
Analyzer IIx (Illumina). The resulting sequence reads
(113 bp) were aligned to the reference genome (NCBI
human genome assembly build 36) with the Burrows-
Wheeler Aligner.8 The average coverage for these four
samples was 863, and each sample had >96% of the
bases covered. Genetic differences with respect to the
reference genome were identified with the SAMtools
variant-calling program,9 which identifies both single-
nucleotide variants and small indels. We focused on
variants annotated as functional, i.e., nonsynonymous,
essential splice-site, stop-gain, stop-loss, and intron-exon-
boundary variants, as well as frame-disrupting indels, by
Figure 2. Protein Attributes of TECPR2
Domain structure and mutation according to UniProt and NCBI
conserved domains.
Top: Conserved domains in the wild-type TECPR2 according to
UniProt. Yellow represents WD (tryptophan-aspartic-acid dipep-
tide) repeats, purple indicates TECPR domains, and blue represents
the polylysin tract.
Bottom: The effect of themutation. Orange indicates the modified
protein sequence resulting from a frameshift (at position 1,139)
leading to a premature stop codon (at position 1,212).using SequenceVariantAnalyzer software.10 We selected
variants that were rare (<3% minor allele frequency
[MAF]) in dbSNP132 and in 909 available control samples
previously subjected to exome and whole-genome se-
quencing as described11 (Table S2). The latter group did
not include any Jewish Bukharian individuals or any
known relatives of the three families and was not enriched
with abnormal neuronal phenotypes.
One homozygous variant was shared among all four
affected individuals and had a MAF ¼ 0 in controls. This
was a single-base deletion of T in exon 16 within TECPR2
(KIAA0329), transcript ENST00000359520 (c.3416delT,
RefSeq accession number NM_014844.3) (Figure S1). The
deletion causes a frameshift (p.Leu1139Argfs*75) leading
to a premature stop codon, resulting in the loss of four
out of six TECPR domains (Figure 2). Genotyping of the
c.3416delT variant by the ABI prism 3100 Genetic
Analyzer (Life Technologies, Carlsbad, CA, USA) showed
perfect cosegregation in all three families (Figure 1A).
This included DNA from a muscle biopsy available for
the deceased fifth individual (II-1 in family B), also found
to be homozygous for the TECPR2 mutation. Subsequent
application of PLINK analysis12 to all high-quality exome
sequence variants showed that a 1 Mb region of homozy-
gosity encompassing TECPR2 at chromosomal region 14q:
102,356,475–103,388,999 (corresponding to rs1904298–
rs2295828 according to NCBI build 37/hg19) was shared
among all four sequenced affected individuals. This
analysis further increased our confidence in the TECPR2
mutation. We note, however, that such support is not
fool proof and that, although unlikely, the culprit could
be elsewhere in the region, including in an untranslated
sequence.The American JouWe also interrogated the exomes of these affected
individuals to determine whether copy-number variants
(CNVs) could explain the observed idiosyncratic HSP
phenotype. We therefore looked for exons that had very
low or zero coverage and that would suggest homozygous
(CNV) deletions, but we found none. In addition, we
applied CoNIFER,13 an algorithm that attempts to detect
deletions and duplications in exome data, but did not
detect any CNVs shared by all affected individuals.
Although CNV detection from exome data is known to
be prone to error,14 this significantly decreases the proba-
bility that the causative variation is a genomic deletion
or duplication.
To better estimate the frequency of the c.3416delT
variant in healthy individuals, we genotyped 1,098 addi-
tional DNA samples from healthy controls that were not
ethnically matched, and we found that none were carriers
(the specific primers used are reported in Table S3). Thus,
overall, this truncation was not found in any of the
2,007 non-Bukharian controls that we checked. We also
genotyped 150 Jewish Bukharian controls and found the
mutation in a heterozygous form in 4 out of the 300
chromosomes, accounting for an allele frequency of
0.013 in this ethnic group. This implies that the disease
could be seen in 1.7 out of 10,000 endogamy couples,
consistent with our identification of three affected families
by an admittedly incomplete screen in a community of
150,000 Israeli Bukharian Jews with likely partial en-
dogamy. To test the effect of the mutation, we derived
full-length cDNA from the human kidney cell line
HEK293 and used PCR-directed mutagenesis to generate
the c.3416delT form of the gene. C-terminal or N-terminal
FLAG-tagged TECPR2 was made by two-step PCR-directed
mutagenesis. We then transfected the constructs into
monkey kidney cell line COS-7, human kidney cell line
HEK293, and human epithelial cell line HeLa; derived total
cDNA; and visualized it by semiquantitative RT-PCR (the
specific primer sets used are reported in Table S3). Tran-
scripts were seen for both the normal and mutated forms
(Figure 3A). We then used FLAG M2 monoclonal antibody
(Sigma Aldrich), human TECPR2 polyclonal antibody
(Sigma Aldrich), or GAPDH monoclonal antibody (Cell
Signaling Technology) to detect TECPR2 forms. TECPR2
was detected by anti-FLAG and anti-TECPR2 immuno-
blotting only in the wild-type, but not in the mutant,
transfection (Figures 3B and 3C). This suggests that the
mistranslated and truncated protein was degraded in these
cells. Inhibiting the proteasome degradation pathway by
MG132 and lactacystin rescued the mutated protein
(Figures 3D and 3E and Figure S2). This indicates that the
mutated protein was targeted for proteasome degradation.
The protein encoded by TECPR2 has recently been
shown by immunoprecipitation-based proteomic analysis
to interact with the six human Atg8 homologs, including
the MAP1LC3 group (LC3). In parallel, it was shown to
be a positive regulator of autophagosome accumulation
by a TECPR2 siRNA approach.15 Autophagy is the majorrnal of Human Genetics 91, 1065–1072, December 7, 2012 1067
Figure 3. Effect of TECPR2 Mutation
(A) Semiquantatative RT-PCR analysis of
the fate of TECPR2 mRNA expression in
COS-7 transfectants for the wild-type
and c.3416delT (‘‘del’’) forms of the tran-
script. ‘‘Mock’’ indicates the empty vector,
‘‘RT(þ)’’ is with reverse transcriptase, and
‘‘RT()’’ is without reverse transcriptase.
The data reveal no effect of the deletion
on PCR-amplified mRNA levels.
(B) Immunoblotting of TECPR2 levels with
FLAG monoclonal antibody. Notations are
the same as in (A). GAPDH was used
as a loading control. The data reveal a
major disappearance of p. Leu1139Argfs*
75 TECPR2. Wild-type TECPR2 is seen at
the expected molecular weight (154 kDa).
(C) Immunoblotting with the TECPR2
antibody. 293T and HeLa are unmodified
cell lines; endogenous TECPR2 is not
detectable. Labels are the same as in (A)
and (B). Wild-type TECPR2, but not the
p.Leu1139Argfs*75 form, is observed in
transfected COS-7 cells.
(D) Effect of proteasome inhibition with
MG132 and lactacystin. Immunoblotting
with FLAG monoclonal antibody for
COS-7 transfectants of C-terminal FLAG-
tagged TECPR2 is shown. Rescue of the
altered TECPR2 and enhancement of
wild-type TECPR2 are revealed upon
proteasome inhibition. The following
abbreviations are used: (), mock trans-
fected; WT, wild-type; del, variant; and
GAPDH, loading control.
(E) Effect of proteasome inhibition with
MG132 and lactacystin. Immunoblotting
with FLAG monoclonal antibody for
COS-7 transfectants of N-terminal FLAG-
tagged TECPR2 is shown. Notations are
the same as in (D).protein degradation system responsible for the turnover of
bulky cellular constituents (protein aggregates and organ-
elles), contributing to cellular homeostasis and survival.16
Dysfunction of autophagy has been proposed as an under-
lying mechanism for several neurodegenerative and
muscle diseases.17,18 We also note that TECPR2 is highly
expressed in the human brain, especially in the prefrontal
cortex,19,20 providing a potential basis for the organ-
specific outcome of the deleterious TECPR2 mutation.
We thus hypothesized that the truncated TECPR2 leads
to modifications of autophagy and thus potentially results
in the observed phenotype.
To test this, we derived skin fibroblasts from an affected
individual (II-2 in family B) and from an unrelated healthy
control, and we examined the effect of the mutation on
the amount and cellular disposition of two endogenous
autophagy-related proteins. The first is the cargo-recruiting
polyubiquitin-binding SQSTM1 (p62), which, together
with cargo proteins, is delivered by autophagosomes to
lysosomal degradation.21,22 The second is the ubiquitin-
like autophagy-initiation MAP1LC3B (LC3), for which1068 The American Journal of Human Genetics 91, 1065–1072, Decestarvation-induced autophagy leads to a transition from
the cytosolic form (LC3I) to the autophagosome-
associated, phosphatidylethanolamine-conjugated form
(LC3II).23,24 We induced autophagy by starvation in
nutrient-poor medium for 6 hr and employed bafilomycin
A, an inhibitor of autophagosome-lysosome fusion, re-
ported to enhance p62 and LC3II levels. The variously
treated fibroblast lysates were subjected to SDS-PAGE fol-
lowed by immunoblotting as described.25 The TECPR2
antibody used in Figure 3C was ineffective in detecting
endogenous protein in the present experiment. The
presence of autophagosomes in the starvation and bafilo-
micyn A condition was evidenced by transmission elec-
tron microscopy (Figure 4C), preformed as previously
described.26 In general, whereas starvation alone led to
a slight diminution in the amount of both proteins, the
addition of bafilomycin A led to a considerable augmenta-
tion of the amounts of p62 and LC3II in the control.
In comparison, the affected-individual sample showed
an across-the-board diminution of p62 and LC3II levels
under all conditions (Figures 4A and 4B). Furthermore,mber 7, 2012
Figure 4. Effect of the Mutation on
Autophagy Markers
(A) Immunoblotting with p62 antibody
and LC3 antibody for skin-fibroblast
lysates of both the affected individual
and the control. Cell lines were used at
an early passage, and there were a
maximum of seven passages. LC3I is the
cytoplasmic form, and LC3II is the phos-
phatidylethanolamine-conjugated form.
GAPDH was used as a loading control.
The following abbreviations are used:
basal, rich medium; str, starvation; and
baf, with the lysosomal inhibitor bafilo-
mycin A.
(B) Summary of three biological replicates
(Figure S3), each in duplicate, for experi-
ments as shown in (A) (with the same
notations) with the use of immunoblot
scan quantitation and normalization by
GAPDH control. Error bars are the SD for
the four replicates. The data show across-
the-board diminution of both LC3II and
p62 amounts in the affected individual as
compared to the control.
(C) Skin fibroblasts of an affected indi-
vidual (right) and a healthy control (left)
were incubated under starvation condi-
tions in the presence of bafilomycin A
for 6 hr, and thin sections were visualized
by transmission electron microscopy as
described.26 Arrows show representative
autophagosomes or autolysosomes and a
possible slight diminution of organelle
accumulation within autophagic bodies
in the affected fibroblasts.we performed siRNA knockdown of TECPR2 in HeLa cells
transfected by DharmaFect 1 (Dharmacon) with siRNA
SMARTpools (50 nM siRNA SMARTpool), consisting of
four RNA duplexes all targeting TECPR2; we then com-
pared them to the nontargeting siRNA control and exam-
ined their autophagy-related phenotype. For validating
the knockdown effect on TECPR2, quantitative real-time
PCR was carried out with platinum SYBR Green qPCR
SuperMix-UDG with ROX (Invitrogen, Life Technologies),
and HPRT was used as the quantification control. TheThe American Journal of Human Geneticsprimer sequences used can be found
in Table S3. By 72 hr, a minimal level
of TECPR2 could be detected in com-
parison to the nontargeting siRNA
control (Figure 5A). In cells in which
TECPR2 was knocked down, we
observed a major reduction of the
bafilomycin-induced LC3II immuno-
reactivity. Of note, p62 amounts
were much less affected by the
mutation (Figure 5B). Using confocal
immunofluorescence analysis as de-
scribed,26 we confirmed these obser-
vations for both proteins (Figures 5C
and 5D and Figure S4).These combined results suggest that the presumed
knockdown of TECPR2 in the HSP subjects brings upon
a decreased accumulation of LC3II-labeled autophago-
somes and attenuates the delivery of LC3II and p62 to lyso-
somal degradation. This indicates that the autophagy
pathway is impaired, but not completely eliminated, given
that we observed a lower impact on p62 protein levels. Of
note, p62 is selectively recruited into autophagosomes,
and therefore, even partial autophagic activity might be
sufficient to deliver this protein to the lysosome.91, 1065–1072, December 7, 2012 1069
Figure 5. TECPR2 Knockdown in HeLa
Cells
(A) Real-time PCR amplification of cDNA
from transfected HeLa cells with either
nontargeting siRNA (Ctrl-siRNA) or a pool
of four TECPR2 siRNAs (TP-siRNA) with
the use of primers specific to TECPR2
(exons 16 and 17).
(B) Immunoblotting with p62 antibody
and LC3 antibody for HeLa cell lysates
transfected with either nontargeting siRNA
(Ctrl-siRNA) or a pool of four TECPR2
siRNAs (TP-siRNA). Notation is the same
as in Figure 4A. LC3II levels are mostly
affected by the knockdown, whereas the
effect is less pronounced for p62.
(C) Basal levels of LC3II and p62 in HeLa
cells in which TECPR2 is knocked down
by siRNA are viewed by immunofluores-
cence confocal microscopy. Notation is
the same as in (B). The following colors
are used: green, LC3 antibody; red, p62
antibody; and yellow, merger of both
signals.
(D) LC3II and p62 levels in the same cells
under the conditions of starvation þ bafi-
lomycin. For nontarget siRNA, punctate
perinuclear structures, stained for both
p62 and LC3II, are most likely autophago-
somes. TECPR2 siRNA knockdown shows
strongly attenuated LC3II signal, whereas
the p62 signal is only slightly diminished.For a group of progressive neurodegenerative diseases
such as Huntington disease (MIM 143100), Alzheimer
disease (MIM 104300), Parkinson disease (MIM 168600),
spinocerebellar ataxias, and amyotrophic lateral sclerosis,
mutant proteins become aggregate prone and hence less
accessible to proteasome degradation; they thus become
more dependent on autophagy for their clearance.18,27,28
These studies have shown that constitutive autophagy is
essential to the survival of motor neurons and that failure
to induce autophagosome formation results in cytosolic
persistence of unsequestered cargo; this could promote
aggregation of intracellular components leading to cyto-
toxicity and could disrupt neural function.29,30 Alterna-
tively, malformation of autophagosomes could lead to
malfunction at downstream cellular pathways, suggesting
that subsequent autophagic steps are modified.
The core neuropathology of HSP is distal degeneration
of the lateral corticospinal tract.31 Many biochemical
mechanisms, includingmitochondrial mechanisms, endo-
plasmic-reticulum shaping, endosomal trafficking, and
microtubule stability, contribute to axonal function within
the corticospinal tracts and affect anterograde and retro-1070 The American Journal of Human Genetics 91, 1065–1072, December 7, 2012grade axonal transport.32 Another
form of recessive, early-onset compli-
cated HSP, SPG20 (Troyer syndrome
[MIM 275900]), shows some simi-
larity to the presently described
SPG49: both syndromes include shortstature and dismorphic features but no eye involvement
or EMG abnormalities. Interestingly, Troyer syndrome
involves a homozygous frameshift mutation, c.1110delA
(p.Lys370Asnfs*30), in SPG20 (MIM 607111, RefSeq
NM_015087.4), leading to degradation of the spartin
protein implicated in endosomal trafficking,33,34 an allied
intracellular-membrane-transport pathway, thus support-
ing the implication of autophagy on the cellular mecha-
nism of spastic paraparesis.
TECPR2 has a relatively high molecular mass (1,411
amino acids), hinting at a molecular linker function. It is
unique in having both WD (tryptophan-aspartic-acid
repeat) domains and TECPR domains, both implicated in
protein-protein interactions involved in diseases.35,36 In
its domain disposition, TECPR2 appears to be specific to
mammals in that lower organisms show orthologs with
either WD or TECPR domains, but not both (Figure S5).
TECPR2 shows relatively weak but significant similarity
(by BLAST via PairsDB37) to two other human proteins
(Figure S5). One is TECPR1, implicated in selective recruit-
ment of bacteria into autophagosomes38–40 and in auto-
phagosome assembly.41 The other is HPS5, underlying
a specific type of Hermansky-Pudlak syndrome (MIM
614074), which involves dysfunction of lysosome-related
organelles.42 The latter information further strengthens
the functional classification of TECPR2 and its disease affil-
iation.
Our observation of three independent Jewish Bukharian
families affected by a unique spectrum of symptoms re-
sulted in the identification of a different form of compli-
cated HSP caused by a variation in TECPR2. We thus
propose calling the present disease SPG49 and adding
it to the SPG list (Table S1)5,6 (also see GeneReviews in
Web Resources). Although the phenotype described here
is quite remarkable, it remains to be established whether
the involvement of an autophagic gene is unique to this
disease subtype and ethnicity.
It would be useful to look in the future for other poten-
tial variants in the same or related genes, especially ones
with evidence of peripheral and autonomic involvement,
in other affected individuals with complicated HSP.
In summary, the results presented here highlight the
importance and diagnostic value of accurate phenotyping
combined with exome and whole-genome sequencing
in deciphering the disease-causing mutation, even in
relatively isolated cases with very few unrelated affected
individuals. Identification of additional families in the
same specific community, or outside it (potentially with
different mutations), would provide further evidence im-
plicating TECPR2 in this added form of HSP.Supplemental Data
Supplemental data include five figures and three tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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